Research programme: cachexia therapy - PhytoMedical Technologies

Drug Profile

Research programme: cachexia therapy - PhytoMedical Technologies

Alternative Names: BDC-03

Latest Information Update: 26 Aug 2011

Price : $50

At a glance

  • Originator PhytoMedical Technologies
  • Developer EMD Millipore; Ricerca Biosciences
  • Class Obesity therapies; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cachexia

Most Recent Events

  • 26 Aug 2011 No development reported - Preclinical for Cachexia in USA (PO)
  • 26 Aug 2011 No development reported - Preclinical for Cachexia in Canada (PO)
  • 12 Jul 2006 Ricerca BioSciences has entered into an agreement with PhytoMedical Technologies to develop BDC 03 for cachexia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top